Mass Tort Advertising Campaign
Necrotizing Enterocolitis (NEC) baby formula litigation targets the manufacturers of bovine-based preterm infant formulas — Abbott (Similac) and Mead Johnson (Enfamil) — over allegations that their products caused or contributed to NEC in premature infants administered formula in neonatal intensive care units. For plaintiff firms, this tort combines a deeply sympathetic injury population, identifiable defendants with national brand recognition, and an active MDL that keeps the litigation visible in the news cycle.
Intake is currently open, and the claimant profile is specific enough to support efficient paid acquisition on Meta platforms. Parents of premature infants who received bovine-based formula in the NICU and subsequently suffered an NEC diagnosis represent the core audience — a group that can be reached with targeted creative and qualified through a structured intake process. MTAA builds and manages these campaigns for plaintiff firms ready to scale their docket.
The NEC baby formula litigation is consolidated in an MDL, reflecting the volume of claims and the shared factual questions around bovine-based preterm infant formula and its association with Necrotizing Enterocolitis in premature newborns. The two primary defendants — Abbott Laboratories, maker of Similac, and Mead Johnson, maker of Enfamil — are among the most recognized infant formula brands in the United States, which means claimants are likely to remember exactly which product was used in the NICU and can often confirm administration through medical records.
NEC is a devastating gastrointestinal condition that primarily affects premature infants, and the NICU setting creates a documented, traceable chain of product use that supports intake qualification. The MDL posture signals that this litigation has reached a stage where plaintiff firms are actively building dockets, making now an appropriate window for sustained paid acquisition before the landscape becomes more competitive.
The creative strategy for NEC baby formula campaigns lives at the intersection of parental grief, institutional trust, and brand recognition. Parents who spent time in a NICU with a premature infant carry vivid memories of that experience — including which formula was used. Meta's targeting environment allows MTAA to reach parents in the appropriate age and life-stage demographics, and the Similac and Enfamil brand names function as immediate recognition triggers in ad copy and creative. The emotional weight of a NEC diagnosis means that when the right parent sees the right message, the connection is immediate; the creative challenge is framing that message with care and clarity rather than sensationalism.
On the intake side, the qualification criteria are concrete enough to support a structured pre-screen: prematurity, NICU admission, formula brand, and NEC diagnosis are all verifiable data points that a trained intake team can confirm efficiently. MTAA structures campaigns to drive volume at the top of the funnel while building in qualification checkpoints that protect your cost-per-signed metric. We manage creative rotation, audience segmentation, and compliance review so your team receives leads that are already pre-screened against the core criteria before they reach a case manager.
Mass Tort Ad Agency runs NEC Baby Formula campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
We build, run, and qualify NEC Baby Formula claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.
Book a strategy call